MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

Search

Pacific Biosciences of California Inc

Cerrado

Sector Salud

1.53 -5.56

Resumen

Variación precio

24h

Actual

Mínimo

1.53

Máximo

1.55

Métricas clave

By Trading Economics

Ingresos

113M

-61M

Ventas

-743K

39M

BPA

-0.2

Margen de beneficio

-151.938

EBITDA

-123M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+42.21 upside

Dividendos

By Dow Jones

Próximas Ganancias

8 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-446M

521M

Apertura anterior

7.09

Cierre anterior

1.53

Noticias sobre sentimiento de mercado

By Acuity

38%

62%

121 / 393 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Pacific Biosciences of California Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

22 feb 2025, 00:16 UTC

Acciones populares

Stocks to Watch: Alamos Gold, Booking Holdings

22 feb 2025, 16:33 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 feb 2025, 15:15 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 feb 2025, 14:32 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 feb 2025, 13:49 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 feb 2025, 13:22 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

21 feb 2025, 23:22 UTC

Principales Noticias

DOGE Aide's IRS Access Won't Include Personal Information -- Update

21 feb 2025, 23:20 UTC

Ganancias

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

21 feb 2025, 22:34 UTC

Charlas de Mercado

L'Oréal Cuts Exposure to Chinese Market, Grows Emerging Markets -- Market Talk

21 feb 2025, 22:12 UTC

Principales Noticias

DOJ Investigates Medicare Billing Practices at UnitedHealth -- 2nd Update

21 feb 2025, 21:54 UTC

Principales Noticias

Why Is Warren Buffett Hoarding So Much Cash? -- 2nd Update

21 feb 2025, 21:51 UTC

Ganancias

Tesla Stock Falls. Recalls and Rivian Are in the News. -- Barrons.com

21 feb 2025, 21:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

21 feb 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 feb 2025, 21:50 UTC

Principales Noticias

DOGE Aide's IRS Access Won't Include Personal Information -- WSJ

21 feb 2025, 21:48 UTC

Charlas de Mercado
Ganancias

L'Oréal Tops Estée Lauder in Luxury U.S. Market, CEO Says -- Market Talk

21 feb 2025, 21:35 UTC

Charlas de Mercado

Bulk of U.S. Imports From Canada Used to Make U.S. Goods -- Market Talk

21 feb 2025, 21:28 UTC

Principales Noticias

Why Is Warren Buffett Hoarding So Much Cash? -- Update

21 feb 2025, 21:24 UTC

Principales Noticias

Major U.S. Stock Indexes Give Up Gains From the Week -- WSJ

21 feb 2025, 21:19 UTC

Charlas de Mercado

Mexico's Inflation Seen Up in Early February -- Market Talk

21 feb 2025, 20:15 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

21 feb 2025, 20:15 UTC

Charlas de Mercado

JPMorgan Chase Branch Expansion Portends Deposit Growth -- Market Talk

21 feb 2025, 20:05 UTC

Charlas de Mercado

Oil Futures Retreat Into the Weekend Again -- Market Talk

21 feb 2025, 19:58 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Gain -- Market Talk

21 feb 2025, 19:29 UTC

Charlas de Mercado

Gold Slides After Finding Record High -- Market Talk

21 feb 2025, 19:26 UTC

Principales Noticias

Major U.S. Stock Indexes Slip; UnitedHealth Pulls Down DJIA -- WSJ

21 feb 2025, 19:05 UTC

Charlas de Mercado

Business Conditions Seen as Favoring Corporate Credit -- Market Talk

21 feb 2025, 19:02 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

21 feb 2025, 19:02 UTC

Charlas de Mercado

Corporate Credit Expected to Be Hit Unevenly by Trade Wars -- Market Talk

21 feb 2025, 19:00 UTC

Charlas de Mercado

Long-Term Treasury Yields Expected to Rise -- Market Talk

Comparación entre iguales

Cambio de precio

Pacific Biosciences of California Inc Esperado

Precio Objetivo

By TipRanks

42.21% repunte

Estimación a 12 meses

Media 2.19 USD  42.21%

Máximo 3.5 USD

Mínimo 1.5 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pacific Biosciences of California Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

3

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.43 / 1.56Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

121 / 393 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company has developed its Single Molecule, Real-Time (SMRT) technology, which enables single molecule, real-time detection of nucleic acid sequences, to address many of the limitations of previous sequencing technologies. The Company’s products include the Sequel II and Sequel IIe instruments and SMRT Cell 8M, which together are capable of sequencing up to approximately eight million deoxyribonucleic acid (DNA) molecules simultaneously, and the previous generation Sequel instrument and Sequel SMRT Cell 1M, which together are capable of sequencing up to one million DNA molecules simultaneously. Its Sequel IIe System increases computational capacity and is designed to enable customers to generate PacBio HiFi reads.